CXChangjing Xu

Changjing Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Changjing Xu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Hou

    The Affiliated Hospital of Southwest Medical University

    1 shared publication
  • Jingwei Li

    Department of Cardiology, People’s Liberation Army General Hospital, Beijing, CN; The George Institute for Global Health, Faculty of Medicine, University of New South Wales, NSW, Sydney, AU; Department of Cardiology, Xinqiao Hospital, Army Military Medical University, Chongqing

    1 shared publication
  • Junlong Zhu

    The Affiliated Hospital of Southwest Medical University

    1 shared publication
  • Liya Fu

    Southwest Medical University

    1 shared publication
  • Wanlong Zhu

    Southwest Medical University

    1 shared publication
  • Xiaoyan Zhong

    Institute of Functional Nano & Soft Materials (FUNSOM) Jiangsu Key Laboratory of Advanced Healthcare Materials & Devices Biomedical‐BasicResearch‐Center (BBRC) of Jiangsu Province Soochow University Suzhou China

    1 shared publication

Latest Publications

  • Open Access

    Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis

    by Xuemei Tao, Changjing Xu, Xiaoyan Zhong, Yao Mou, Jingwei Li, Xuping Yang, Yilan Huang

    Objective: To compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.Methods: We retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.Results: 416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (p = 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (p = 1.0). There were no statistical differences between Biapenem and Meropenem.Conclusion: In general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP.

  • Open Access

    Clinical features and risk factors analysis for poor outcomes of severe community-acquired pneumonia (SCAP) in children: a nomogram prediction model

    by Changjing Xu, Xuemei Tao, Liya Fu, Junlong Zhu, Xuping Yang, Chao Hou, Yujie Liu, Wanlong Zhu, Yilan Huang

    Background: Early prediction of poor outcomes (PO) is of great significance to the improvement of the longterm prognosis of children with a diagnosis of severe community-acquired pneumonia (SCAP).The study aimed to explore the risk factors for PO of SCAP in children. We further aimed to develop and validate a PO-predictive nomogram model for SCAP in children. Methods: A population-based, retrospective case-control study was conducted in children with a diagnosis of SCAP who were hospitalized in our hospital from August 1, 2018 to October 31, 2021. Based on the occurrence of poor outcomes (PO), children were divided into PO and the non-PO groups. The multivariate logistic regression model was used to construct the nomogram model. Results: A total of 300 children with a diagnosis of SCAP were included, and 56 children had PO. The results of multivariate logistic regression analysis revealed that the possible independent risk factors for PO were comorbidity and invasive mechanical ventilation (IMV). In internal validation, the model displayed good discrimination with a C-index of 0.866 (95% CI: 0.772~0.960) and high quality of calibration plots in the nomogram model was noted. Conclusions: The nomogram model presented good discrimination and calibration in estimating the risk of PO among pediatric patients with a diagnosis of SCAP.